FDA confirms primary goal for Dimerix’s DMX-200 trial to treat FSGS
The US Food and Drug Administration (FDA) has confirmed proteinuria as an acceptable primary endpoint in Dimerix ‘s Phase III…
All articles by
-
-
Pacira’s gene therapy shows sustained benefits in trial for knee osteoarthritis
Pacira BioSciences has announced that its gene therapy candidate, PCRX-201 (enekinragene inzadenovec), has demonstrated sustained improvements in knee pain, function,…
-
Kura doses first subjects in trial of ziftomenib for advanced GIST
Kura Oncology has dosed the first subjects in the open-label Phase Ia/Ib KOMET-015 trial, evaluating the oral investigational menin inhibitor…
-
US FDA approves BlackfinBio’s gene therapy trial for hereditary spastic paraplegia
The US Food and Drug Administration has cleared BlackfinBio's investigational new drug (IND) application for a Phase I/II trial of…
-
Pfizer’s sasanlimab and BCG combo therapy improves EFS in bladder cancer trial
US-based pharmaceutical company Pfizer has reported positive results from a Phase III trial of sasanlimab and Bacillus Calmette-Guérin (BCG) for…
-
MSD reports outcomes from Keytruda combination trial for head and neck cancer
US-based pharmaceutical company MSD has reported outcomes from a Phase III trial of Keytruda (pembrolizumab) for treating resected, locally advanced head…
-
CERo announces SCRI as main site for trial of CER-1236 to treat AML
CERo Therapeutics has announced that Colorado Blood Cancer Institute’s (CBCI) Sarah Cannon Research Institute (SCRI), US, will be the main site…
-
Renibus completes enrolment in RBT-1 trial to reduce post-cardiac surgery risk
Renibus Therapeutics has completed subject enrolment for the randomised Phase III PROTECT trial, assessing RBT-1 (stannic protoporfin/iron sucrose) in minimising…
-
Clinical ink introduces AI-powered trial analytics dashboard
Clinical ink has launched the AI-powered, fully integrated analytics dashboard, TrialLens, designed to transform the visualisation, querying, and interpretation of…
-
Dosing begins in Tiziana Life Sciences’ trial of foralumab for na-SPMS
Tiziana Life Sciences has announced the commencement of dosing in the fourth clinical site of the company’s Phase II trial…
